211 related articles for article (PubMed ID: 26310614)
1. Potential analgesic effects of a novel N-acylethanolamine acid amidase inhibitor F96 through PPAR-α.
Yang L; Li L; Chen L; Li Y; Chen H; Li Y; Ji G; Lin D; Liu Z; Qiu Y
Sci Rep; 2015 Aug; 5():13565. PubMed ID: 26310614
[TBL] [Abstract][Full Text] [Related]
2. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
Sasso O; Moreno-Sanz G; Martucci C; Realini N; Dionisi M; Mengatto L; Duranti A; Tarozzo G; Tarzia G; Mor M; Bertorelli R; Reggiani A; Piomelli D
Pain; 2013 Mar; 154(3):350-360. PubMed ID: 23218523
[TBL] [Abstract][Full Text] [Related]
3. NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI).
Li Y; Zhou P; Hu T; Ren J; Xu Y; Qiu Y; Lu C; Li Y
Eur J Pharmacol; 2021 Dec; 912():174561. PubMed ID: 34655598
[TBL] [Abstract][Full Text] [Related]
4. N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis.
Zhou P; Xiang L; Yang Y; Wu Y; Hu T; Liu X; Lin F; Xiu Y; Wu K; Lu C; Ren J; Qiu Y; Li Y
Pharmacol Res; 2019 Jul; 145():104264. PubMed ID: 31063807
[TBL] [Abstract][Full Text] [Related]
5. Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.
Jin W; Yang L; Yi Z; Fang H; Chen W; Hong Z; Zhang Y; Zhang G; Li L
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32326173
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors.
Malamas MS; Farah SI; Lamani M; Pelekoudas DN; Perry NT; Rajarshi G; Miyabe CY; Chandrashekhar H; West J; Pavlopoulos S; Makriyannis A
Bioorg Med Chem; 2020 Jan; 28(1):115195. PubMed ID: 31761726
[TBL] [Abstract][Full Text] [Related]
7. Advances in the discovery of N-acylethanolamine acid amidase inhibitors.
Bandiera T; Ponzano S; Piomelli D
Pharmacol Res; 2014 Aug; 86():11-7. PubMed ID: 24798679
[TBL] [Abstract][Full Text] [Related]
8. Inflammation-restricted anti-inflammatory activities of a N-acylethanolamine acid amidase (NAAA) inhibitor F215.
Li Y; Zhou P; Chen H; Chen Q; Kuang X; Lu C; Ren J; Qiu Y
Pharmacol Res; 2018 Jun; 132():7-14. PubMed ID: 29572189
[TBL] [Abstract][Full Text] [Related]
9.
Piomelli D; Scalvini L; Fotio Y; Lodola A; Spadoni G; Tarzia G; Mor M
J Med Chem; 2020 Jul; 63(14):7475-7490. PubMed ID: 32191459
[No Abstract] [Full Text] [Related]
10. Progress in the development of β-lactams as N-Acylethanolamine Acid Amidase (NAAA) inhibitors: Synthesis and SAR study of new, potent N-O-substituted derivatives.
Petracca R; Ponzano S; Bertozzi SM; Sasso O; Piomelli D; Bandiera T; Bertozzi F
Eur J Med Chem; 2017 Jan; 126():561-575. PubMed ID: 27915171
[TBL] [Abstract][Full Text] [Related]
11. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation.
Solorzano C; Zhu C; Battista N; Astarita G; Lodola A; Rivara S; Mor M; Russo R; Maccarrone M; Antonietti F; Duranti A; Tontini A; Cuzzocrea S; Tarzia G; Piomelli D
Proc Natl Acad Sci U S A; 2009 Dec; 106(49):20966-71. PubMed ID: 19926854
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as anti-inflammatory compounds.
Li Y; Yang L; Chen L; Zhu C; Huang R; Zheng X; Qiu Y; Fu J
PLoS One; 2012; 7(8):e43023. PubMed ID: 22916199
[TBL] [Abstract][Full Text] [Related]
13. Palmitoylethanolamide (PEA) reduces postoperative adhesions after experimental strabismus surgery in rabbits by suppressing canonical and non-canonical TGFβ signaling through PPARα.
Li Y; Zhao S; Xu S; Li Y; Wang C; Ren J; Li F; Hu X; Lin K; Qiu Y; Xiu Y
Biochem Pharmacol; 2021 Feb; 184():114398. PubMed ID: 33385371
[TBL] [Abstract][Full Text] [Related]
14. Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain.
Petrosino S; Ahmad A; Marcolongo G; Esposito E; Allarà M; Verde R; Cuzzocrea S; Di Marzo V
Pharmacol Res; 2015 Jan; 91():9-14. PubMed ID: 25447594
[TBL] [Abstract][Full Text] [Related]
15. N-acylethanolamine hydrolyzing acid amidase inhibition: tools and potential therapeutic opportunities.
Bottemanne P; Muccioli GG; Alhouayek M
Drug Discov Today; 2018 Aug; 23(8):1520-1529. PubMed ID: 29567427
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, structure-activity, and structure-stability relationships of 2-substituted-N-(4-oxo-3-oxetanyl) N-acylethanolamine acid amidase (NAAA) inhibitors.
Vitale R; Ottonello G; Petracca R; Bertozzi SM; Ponzano S; Armirotti A; Berteotti A; Dionisi M; Cavalli A; Piomelli D; Bandiera T; Bertozzi F
ChemMedChem; 2014 Feb; 9(2):323-36. PubMed ID: 24403170
[TBL] [Abstract][Full Text] [Related]
17. N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.
Alhouayek M; Bottemanne P; Makriyannis A; Muccioli GG
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 May; 1862(5):474-484. PubMed ID: 28065729
[TBL] [Abstract][Full Text] [Related]
18. 3-Aminoazetidin-2-one derivatives as N-acylethanolamine acid amidase (NAAA) inhibitors suitable for systemic administration.
Fiasella A; Nuzzi A; Summa M; Armirotti A; Tarozzo G; Tarzia G; Mor M; Bertozzi F; Bandiera T; Piomelli D
ChemMedChem; 2014 Jul; 9(7):1602-14. PubMed ID: 24828120
[TBL] [Abstract][Full Text] [Related]
19. A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation.
Ribeiro A; Pontis S; Mengatto L; Armirotti A; Chiurchiù V; Capurro V; Fiasella A; Nuzzi A; Romeo E; Moreno-Sanz G; Maccarrone M; Reggiani A; Tarzia G; Mor M; Bertozzi F; Bandiera T; Piomelli D
ACS Chem Biol; 2015 Aug; 10(8):1838-46. PubMed ID: 25874594
[TBL] [Abstract][Full Text] [Related]
20. N-acylethanolamine-hydrolysing acid amidase: A new potential target to treat paclitaxel-induced neuropathy.
Toma W; Caillaud M; Patel NH; Tran TH; Donvito G; Roberts J; Bagdas D; Jackson A; Lichtman A; Gewirtz DA; Makriyannis A; Malamas MS; Imad Damaj M
Eur J Pain; 2021 Jul; 25(6):1367-1380. PubMed ID: 33675555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
